Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since May 14 · above the Ichimoku cloud · RSI 68 · MACD below its signal · at its 52-week high
None of the 29 investors followed here reported a position in SPI.L in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SPI.L trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | Barclays Plc | Decrease at price 3.28 per share. | 4.5K | $14.64K |
| Oct 6, 2026 | American Century Investment Management, Inc | Bought at price 3.26 per share. | 4K | $12.95K |
| Oct 5, 2026 | Barclays Plc | Decrease at price 3.28 per share. | 12.1K | $39.73K |
| Oct 5, 2026 | Dimensional Fund Advisors, L.P. | Decrease at price 3.28 per share. | 1.4K | $4.43K |
| Oct 4, 2026 | Barclays Plc | Decrease at price 3.26 per share. | 19.9K | $64.83K |
| Oct 1, 2026 | Barclays Plc | Decrease at price 3.27 per share. | 21.2K | $69.21K |
| Oct 1, 2026 | American Century Investment Management, Inc | Bought at price 3.27 per share. | 1.4K | $4.69K |
| Oct 1, 2026 | Soci�T� G�N�Rale S.A | Sold at price 3.27 per share. | 5K | $16.33K |
| Sep 30, 2026 | Soci�T� G�N�Rale S.A | Bought at price 3.25 per share. | 941.7K | $3.06M |
| Sep 30, 2026 | American Century Investment Management, Inc | Bought at price 3.27 per share. | 11.9K | $39.04K |
| Sep 30, 2026 | Barclays Plc | Decrease at price 3.27 per share. | 12.2K | $40.04K |
| Sep 29, 2026 | Barclays Plc | Decrease at price 3.26 per share. | 19.2K | $62.66K |
| Sep 29, 2026 | American Century Investment Management, Inc | Bought at price 3.26 per share. | 3.4K | $11.03K |
| Sep 29, 2026 | J.P. Morgan Securities Plc | — | 3.26M | — |
| Sep 29, 2026 | Soci�T� G�N�Rale S.A | Bought at price 3.26 per share. | 2.69M | $8.79M |
| Sep 29, 2026 | Soci�T� G�N�Rale S.A | Sold at price 3.26 per share. | 7.3K | $23.87K |
| Sep 28, 2026 | Soci�T� G�N�Rale S.A | Bought at price 3.25 per share. | 242.7K | $789.80K |
| Sep 28, 2026 | American Century Investment Management, Inc | Bought at price 3.24 per share. | 4K | $12.82K |
| Sep 28, 2026 | Barclays Plc | Increase at price 3.25 per share. | 17.2K | $56.08K |
| Sep 27, 2026 | Barclays Plc | Increase at price 3.26 per share. | 35.5K | $115.58K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 22.2 | -0.5 | -28.1 | 11.6 | 35.6 | -2.7 | 8.6 | 0.6 | 4.9 | 0.4 | +48.2% | ||
| 2025 | 3.5 | -3.2 | -21.7 | 9.0 | 0.1 | 15.7 | -2.7 | -0.5 | 14.7 | -5.8 | -2.1 | -27.2 | −26.1% |
| 2024 | 4.6 | -4.9 | 2.9 | 6.3 | 2.6 | -7.1 | 9.6 | -1.4 | -7.3 | -8.3 | 4.4 | 0.2 | −0.2% |
| 2023 | 6.6 | -1.0 | -11.6 | 7.5 | -2.4 | -4.7 | 1.4 | 0.9 | 7.4 | -8.6 | 4.2 | 1.8 | −0.7% |
| 2022 | -5.0 | -2.1 | 5.2 | -11.7 | 2.1 | 6.6 | 1.1 | -2.1 | -7.3 | 0.7 | 6.0 | -0.9 | −8.8% |
| 2021 | 3.7 | -9.1 | 14.1 | 19.6 | 22.8 | 0.2 | -9.8 | 5.9 | -12.3 | 14.1 | -1.5 | 8.0 | +60.9% |
| 2020 | -7.7 | -11.8 | -32.4 | 23.7 | -1.7 | -10.4 | -11.6 | 22.1 | 3.5 | 25.3 | 12.8 | 15.8 | +9.4% |
| 2019 | 14.3 | 2.4 | 1.6 | 3.3 | -8.7 | -2.1 | -5.3 | -7.1 | 6.0 | 4.7 | 5.7 | 15.0 | +30.4% |
| 2018 | -3.8 | -5.8 | -9.0 | 9.0 | 9.2 | 0.6 | -1.0 | -30.5 | -17.3 | -17.6 | 5.8 | -12.3 | −57.1% |
| 2017 | -7.4 | 4.3 | -0.6 | 4.3 | 1.2 | -5.2 | 6.4 | -5.9 | -30.7 | 32.1 | -16.9 | 2.8 | −24.9% |
| 2016 | 3.3 | 7.0 | 3.8 | -8.7 | 7.0 | -4.7 | -3.3 | 8.0 | 13.1 | -5.7 | -4.8 | -4.7 | +7.9% |
| 2015 | -15.5 | -1.6 | 18.4 | -14.3 | 12.5 | -7.7 | 16.1 | -7.9 | 1.1 | 4.1 | -13.5 | -3.5 | −17.7% |
| 2014 | 19.2 | 15.0 | -3.2 | 12.1 | 21.0 | +80.1% |
Buy / hold / sell counts
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It operates in two segments: Hospitals Business and Primary Care. The company provides diagnostics, inpatient, day case, and outpatient care in areas, including orthopedics, gynaecology, cardiology, neurology, oncology, and general surgery; and primary care needs of outpatients, such as GP services, occupational health services, and mental and physical health services. It also offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, digestive and bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. In addition, the company provides eye surgery and treatments, family planning, gastroenterology, general medicine, haematology, hand surgery, hip and knee replacement treatment, and heart and kidney treatments. Further, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory medicine, and rheumatology; and scans and investigations, skin treatments, spinal neurosurgery, sports science, urology, vascular surgery, weight loss, and women's health. Additionally, the company provides treatments in the areas of breast enlargement, cataract removal surgery, gastric bypass surgery, and prostate surgery; and offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
No recent headlines.